301096 百诚医药
已收盘 08-21 15:00:00
资讯
新帖
简况
百诚医药（301096）披露全资子公司部分药品中选国家药品集中采购公告，8月11日股价上涨2.36%
证券之星 · 08-11
百诚医药（301096）披露全资子公司部分药品中选国家药品集中采购公告，8月11日股价上涨2.36%
百诚医药最新公告：全资子公司西格列汀二甲双胍缓释片中选第十二批国家药品集采
证券之星 · 08-11
百诚医药最新公告：全资子公司西格列汀二甲双胍缓释片中选第十二批国家药品集采
股市必读：百诚医药（301096）7月31日董秘有最新回复
证券之星 · 08-03
股市必读：百诚医药（301096）7月31日董秘有最新回复
百诚医药（301096）披露创新药BIOS0635-048片获临床试验批准通知书，7月27日股价上涨2.08%
证券之星 · 07-27
百诚医药（301096）披露创新药BIOS0635-048片获临床试验批准通知书，7月27日股价上涨2.08%
百诚医药最新公告：创新药BIOS0635-048片获临床试验批准通知书
证券之星 · 07-27
百诚医药最新公告：创新药BIOS0635-048片获临床试验批准通知书
7月17日百诚医药（301096）龙虎榜数据：机构净卖出2228.36万元，北向资金净买入472.86万元
证券之星 · 07-17
7月17日百诚医药（301096）龙虎榜数据：机构净卖出2228.36万元，北向资金净买入472.86万元
百诚医药(301096.SZ)：2类改良型新药左乙拉西坦缓释颗粒获得药品注册证书
智通财经 · 07-17
百诚医药(301096.SZ)：2类改良型新药左乙拉西坦缓释颗粒获得药品注册证书
百诚医药最新公告：创新药BIOS0629-109片获临床试验批准
证券之星 · 07-02
百诚医药最新公告：创新药BIOS0629-109片获临床试验批准
百诚医药：公司目前暂未布局青蒿素相关原材料或产品
证券之星 · 06-30
百诚医药：公司目前暂未布局青蒿素相关原材料或产品
百诚医药：决定终止筹划控制权变更事项
证券之星 · 06-30
百诚医药：决定终止筹划控制权变更事项
每周股票复盘：百诚医药（301096）2026年推限制性股票激励计划
证券之星 · 06-21
每周股票复盘：百诚医药（301096）2026年推限制性股票激励计划
百诚医药涨7.23%，东吴证券一个月前给出“买入”评级
证券之星 · 06-04
百诚医药涨7.23%，东吴证券一个月前给出“买入”评级
百诚医药（301096）披露2026年限制性股票激励计划（草案），6月2日股价下跌3.51%
证券之星 · 06-02
百诚医药（301096）披露2026年限制性股票激励计划（草案），6月2日股价下跌3.51%
开盘20CM跌停！CRO龙头百诚医药易主告吹，逾1万股民受波及
21世纪经济报道 · 06-01
开盘20CM跌停！CRO龙头百诚医药易主告吹，逾1万股民受波及
医保局发布医保目录调整方案；内蒙古检查售卖集采药违规药店
21世纪经济报道 · 06-01
医保局发布医保目录调整方案；内蒙古检查售卖集采药违规药店
百诚医药宣布终止控股权变更计划，6月1日复牌
美股速递 · 05-31
百诚医药宣布终止控股权变更计划，6月1日复牌
百诚医药最新公告：终止筹划控制权变更事项股票复牌
证券之星 · 05-31
百诚医药最新公告：终止筹划控制权变更事项股票复牌
百诚医药(301096.SZ)：相关各方正在积极推进公司控制权变更事项 继续停牌
智通财经 · 05-26
百诚医药(301096.SZ)：相关各方正在积极推进公司控制权变更事项 继续停牌
连续两年亏损、长期处于破发状态，百诚医药谋划易主
蓝鲸财经 · 05-26
连续两年亏损、长期处于破发状态，百诚医药谋划易主
百诚医药宣布自5月25日起停牌 因控制权或生变
美股速递 · 05-24
百诚医药宣布自5月25日起停牌 因控制权或生变
暂无数据
公司概况
公司名称：
杭州百诚医药科技股份有限公司
所属行业：
研究和试验发展
上市日期：
2021-12-20
主营业务：
杭州百诚医药科技股份有限公司的主营业务是为各类制药企业、医药研发投资企业提供医药技术受托研发服务（CRO业务）、研发技术成果转化服务、定制研发生产服务（CDMO）。公司的主要产品是药学研究、临床试验、注册申报、研发技术成果转化、定制研发生产服务（CDMO）、自主创新药物研发、受托创新药物研发。公司先后获得“国家高新技术企业”“省级重点企业研究院”“省级技术中心”等荣誉。
发行价格：
79.60
{"stockData":{"symbol":"301096","market":"SZ","secType":"STK","nameCN":"百诚医药","latestPrice":49.77,"timestamp":1787295831000,"preClose":50.9,"halted":0,"volume":2471508,"delay":0,"changeRate":-0.0222,"floatShares":83090000,"shares":109000000,"eps":-0.4705,"marketStatus":"已收盘","change":-1.13,"latestTime":"08-21 15:00:00","open":49.88,"high":50.1,"low":48.8,"amount":122000000,"amplitude":0.0255,"askPrice":49.78,"askSize":3,"bidPrice":49.76,"bidSize":4,"shortable":0,"etf":0,"ttmEps":-0.4705,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1787535000000},"marketStatusCode":5,"adr":0,"adjPreClose":50.9,"symbolType":"stock","openAndCloseTimeList":[[1787275800000,1787283000000],[1787288400000,1787295600000]],"highLimit":55.99,"lowLimit":45.81,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":109228284,"isCdr":false,"pbRate":2.22,"roa":"--","roe":"0.51%","epsLYR":-0.83,"committee":0.208511,"marketValue":5436000000,"turnoverRate":0.0297,"status":1,"floatMarketCap":4135000000},"requestUrl":"/m/hq/s/301096/tweets","defaultTab":"tweets","newsList":[{"id":"2658916103","title":"百诚医药（301096）披露全资子公司部分药品中选国家药品集中采购公告，8月11日股价上涨2.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658916103","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658916103?lang=zh_cn&edition=full","pubTime":"2026-08-11 22:10","pubTimestamp":1786457412,"startTime":"0","endTime":"0","summary":"截至2026年8月11日收盘，百诚医药报收于46.84元，较前一交易日上涨2.36%，最新总市值为51.16亿元。公司于近日披露《关于全资子公司部分药品中选国家药品集中采购的公告》。公告显示，杭州百诚医药科技股份有限公司全资子公司浙江赛默制药有限公司参与国家组织的第十二批药品集中采购，西格列汀二甲双胍缓释片两个规格产品中选。目前采购协议签订等后续事项仍存在不确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081100038025.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301096","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658999534","title":"百诚医药最新公告：全资子公司西格列汀二甲双胍缓释片中选第十二批国家药品集采","url":"https://stock-news.laohu8.com/highlight/detail?id=2658999534","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658999534?lang=zh_cn&edition=full","pubTime":"2026-08-11 17:41","pubTimestamp":1786441266,"startTime":"0","endTime":"0","summary":"百诚医药(301096.SZ)公告称，公司全资子公司浙江赛默制药有限公司参与第十二批全国药品集中采购，西格列汀二甲双胍缓释片中选。该药品适用于成人2型糖尿病患者，规格为磷酸西格列汀50mg/100mg联合盐酸二甲双胍500mg/1000mg。2025年度该产品暂未实现销售收入，若后续签订采购合同并实施，将有利于产品放量销售及市场开拓，对公司未来经营业绩产生积极影响。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081100028662.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301096","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656634373","title":"股市必读：百诚医药（301096）7月31日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2656634373","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656634373?lang=zh_cn&edition=full","pubTime":"2026-08-03 03:38","pubTimestamp":1785699494,"startTime":"0","endTime":"0","summary":"截至2026年7月31日收盘，百诚医药报收于37.82元，上涨5.17%，换手率4.32%，成交量3.59万手，成交额1.36亿元。董秘最新回复投资者： 公司与耀速科技的合作主要涉及哪些方面董秘： 尊敬的投资者您好，在前沿技术、产业资源与研发能力上，公司与包括耀速科技在内的行业伙伴一直保持着开放性的交流与探索。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080300001467.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301096","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654468140","title":"百诚医药（301096）披露创新药BIOS0635-048片获临床试验批准通知书，7月27日股价上涨2.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2654468140","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654468140?lang=zh_cn&edition=full","pubTime":"2026-07-27 22:20","pubTimestamp":1785162035,"startTime":"0","endTime":"0","summary":"截至2026年7月27日收盘，百诚医药报收于39.2元，较前一交易日上涨2.08%，最新总市值为42.82亿元。该股当日开盘38.38元，最高40.77元，最低38.12元，成交额达1.63亿元，换手率为4.98%。公司于近日披露《关于创新药BIOS0635-048片获得临床试验批准通知书的公告》。公司近期业绩不会因此次获批产生重大影响，后续将按法规推进临床试验，研发过程存在不确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072700034875.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","301096","BK1574","06978","159992","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654382016","title":"百诚医药最新公告：创新药BIOS0635-048片获临床试验批准通知书","url":"https://stock-news.laohu8.com/highlight/detail?id=2654382016","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2654382016?lang=zh_cn&edition=full","pubTime":"2026-07-27 17:28","pubTimestamp":1785144490,"startTime":"0","endTime":"0","summary":"百诚医药(301096.SZ)公告称，公司自主研发的创新药BIOS0635-048片获得国家药品监督管理局临床试验批准通知书，同意本品单药在晚期实体瘤中开展临床试验。该药物为新型小分子抑制剂，拟用于多种实体瘤的治疗，目前全球尚无针对该靶点的药物获批上市。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072700022436.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","159992","301096","06978","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652740103","title":"7月17日百诚医药（301096）龙虎榜数据：机构净卖出2228.36万元，北向资金净买入472.86万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2652740103","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652740103?lang=zh_cn&edition=full","pubTime":"2026-07-17 17:46","pubTimestamp":1784281612,"startTime":"0","endTime":"0","summary":"证券之星消息，沪深交易所2026年7月17日公布的交易公开信息显示，百诚医药因日跌幅达到15%的前5只证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2026年7月17日收盘，百诚医药报收于41.59元，下跌20.0%，跌停，换手率10.57%，成交量8.79万手，成交额3.93亿元。从龙虎榜公布的当日买卖数据来看，机构合计净卖出2228.36万元，北向资金合计净买入472.86万元。深股通专用、沪股通专用为北向资金的交易席位。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700032802.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301096","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652640164","title":"百诚医药(301096.SZ)：2类改良型新药左乙拉西坦缓释颗粒获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2652640164","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652640164?lang=zh_cn&edition=full","pubTime":"2026-07-17 17:34","pubTimestamp":1784280869,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百诚医药(301096.SZ)发布公告，公司全资子公司浙江赛默制药有限公司近日收到国家药品监督管理局核准签发的左乙拉西坦缓释颗粒的药品注册证书。该药品为2.2类改良型新药，适用于12岁及以上的癫痫患者部分性发作的加用治疗。相比已上市的普通片和缓释片等剂型，缓释颗粒更适用于儿童和吞咽困难患者，提高了患者的依从性，有较为明显的临床优势。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469060.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"百诚医药(301096.SZ)：2类改良型新药左乙拉西坦缓释颗粒获得药品注册证书","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0216","301096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648501800","title":"百诚医药最新公告：创新药BIOS0629-109片获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2648501800","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648501800?lang=zh_cn&edition=full","pubTime":"2026-07-02 18:31","pubTimestamp":1782988287,"startTime":"0","endTime":"0","summary":"百诚医药(301096.SZ)公告称，公司与浙江众神创新医药科技有限公司合作研发的创新药BIOS0629-109片获得国家药监局临床试验批准通知书，同意开展单药在晚期恶性肿瘤的临床试验。该药品为1类化学药，是一种新型XPO1抑制剂。公司与众神创新于2025年11月达成独家授权合作，公司负责研发、临床试验及注册申报等工作，上市后享有销售额10%的提成收益。本次获批对近期业绩无重大影响，后续临床试验及上市存在不确定性。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070200034479.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159992","BK1161","301096","BK1574","BK0216","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647813355","title":"百诚医药：公司目前暂未布局青蒿素相关原材料或产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2647813355","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647813355?lang=zh_cn&edition=full","pubTime":"2026-06-30 11:33","pubTimestamp":1782790436,"startTime":"0","endTime":"0","summary":"证券之星消息，百诚医药(301096)06月29日在投资者关系平台上答复投资者关心的问题。投资者提问：你好，公司有青蒿素相关产原材料或产品吗？百诚医药回复：尊敬的投资者您好，公司目前暂未布局青蒿素相关原材料或产品，感谢您的关注。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026063000017951.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301096","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647581369","title":"百诚医药：决定终止筹划控制权变更事项","url":"https://stock-news.laohu8.com/highlight/detail?id=2647581369","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2647581369?lang=zh_cn&edition=full","pubTime":"2026-06-30 11:33","pubTimestamp":1782790436,"startTime":"0","endTime":"0","summary":"证券之星消息，百诚医药(301096)06月29日在投资者关系平台上答复投资者关心的问题。投资者提问：实控人此前曾增持股份，本次股权转让中，交易方报价溢价约20%-30%，未达到实控人50%左右的预期溢价。请问终止转让，是否是基于对公司后续发展的信心，坚持认可公司更高价值？百诚医药回复：尊敬的投资者您好，相关交易方经慎重考虑、磋商，认真听取各方意见，决定终止筹划控制权变更事项。公司严格按照信息披露的相关规定履行信息披露义务，尚未公开披露交易方报价等信息，请以公司公开披露信息为准。感谢您的关注。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026063000017952.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301096","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2645096152","title":"每周股票复盘：百诚医药（301096）2026年推限制性股票激励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2645096152","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2645096152?lang=zh_cn&edition=full","pubTime":"2026-06-21 03:13","pubTimestamp":1781982789,"startTime":"0","endTime":"0","summary":"本周关注点来自公司公告汇总：百诚医药审议通过2026年限制性股票激励计划（草案）及相关议案。公司公告汇总杭州百诚医药科技股份有限公司于2026年6月17日召开2026年第一次临时股东会，采用现场与网络投票结合方式，审议通过选举第四届董事会非独立董事、续聘天健会计师事务所、2026年限制性股票激励计划（草案）及其摘要、实施考核管理办法、提请股东会授权董事会办理股权激励相关事宜等议案。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026062100001031.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640534461","title":"百诚医药涨7.23%，东吴证券一个月前给出“买入”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2640534461","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640534461?lang=zh_cn&edition=full","pubTime":"2026-06-04 16:46","pubTimestamp":1780562784,"startTime":"0","endTime":"0","summary":"今日百诚医药（301096）涨7.23%，收盘报58.74元。2026年4月29日，东吴证券研究员朱国广,苏丰,邹行健发布了对百诚医药的研报《2025年报&2026一季报点评：26Q1利润超预期，创新管线持续推进》，该研报对百诚医药给出“买入”评级。证券之星数据中心根据近三年发布的研报数据计算，该研报作者对此股的盈利预测准确度为69.92%。证券之星数据中心计算显示，对该股盈利预测较准的分析师团队为西部证券的吴天昊。百诚医药（301096）个股概况：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060400028748.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301096","601555"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640911335","title":"百诚医药（301096）披露2026年限制性股票激励计划（草案），6月2日股价下跌3.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640911335","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640911335?lang=zh_cn&edition=full","pubTime":"2026-06-02 17:42","pubTimestamp":1780393356,"startTime":"0","endTime":"0","summary":"截至2026年6月2日收盘，百诚医药报收于56.35元，较前一交易日下跌3.51%，最新总市值为61.55亿元。该股当日开盘58.0元，最高60.41元，最低56.31元，成交额达4.15亿元，换手率为8.56%。近日，杭州百诚医药科技股份有限公司披露《2026年限制性股票激励计划（草案）》。公告显示，本次激励计划拟采用第二类限制性股票形式，股票来源为定向发行A股普通股，拟授予不超过500.00万股，占公司总股本的4.58%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060200034437.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","301096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640798290","title":"开盘20CM跌停！CRO龙头百诚医药易主告吹，逾1万股民受波及","url":"https://stock-news.laohu8.com/highlight/detail?id=2640798290","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640798290?lang=zh_cn&edition=full","pubTime":"2026-06-01 09:47","pubTimestamp":1780278420,"startTime":"0","endTime":"0","summary":"公告一出，引发市场对这家CRO龙头易主的种种猜想。财务数据显示，2025年，百诚医药实现营业总收入6.78亿元，同比下降15.45%；归母净利润则连续第二年出现亏损，亏损额从上年同期的5274.28万元扩大至9039.55万元。公司2026年一季度实现净利润1281.25万元，成功扭亏为盈。公司称，业绩改善主要得益于仿制药CRO/CDMO业务逐步企稳、集采中标品种商业化稳步开展以及降本增效措施取得成效。Wind数据显示，百诚医药股东户数月1.12万名。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/wm/2026-06-01/doc-inhzwist5284387.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-06-01/doc-inhzwist5284387.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0216","301096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640981365","title":"医保局发布医保目录调整方案；内蒙古检查售卖集采药违规药店","url":"https://stock-news.laohu8.com/highlight/detail?id=2640981365","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640981365?lang=zh_cn&edition=full","pubTime":"2026-06-01 08:01","pubTimestamp":1780272073,"startTime":"0","endTime":"0","summary":"药械审批国家医保局发布2026年国家医保目录调整工作方案5月31日，国家医保局发布《2026年国家基本医疗保险、生育保险和工伤保险药品目录及商业健康保险创新药品目录调整工作方案》《2026年国家基本医疗保险、生育保险和工伤保险药品目录及商业健康保险创新药品目录调整申报指南》《谈判药品续约规则》以及《非独家药品竞价规则》。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202606013755285483.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202606013755285483.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0239","BK0175","BK0188","301096","BK0028","BK0114","300562","600196","600513","BK0251","600521","BK0012","BK0070","BK0201","BK0250","IPOS","BK0060","BK0196","301263","BK0185","BK0109","BK0096","BK0183","BK0216","BK0187"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125892899","title":"百诚医药宣布终止控股权变更计划，6月1日复牌","url":"https://stock-news.laohu8.com/highlight/detail?id=1125892899","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1125892899?lang=zh_cn&edition=full","pubTime":"2026-05-31 16:32","pubTimestamp":1780216363,"startTime":"0","endTime":"0","summary":"杭州百诚医药科技股份有限公司发布公告，其筹划中的控制权变更事项已决定终止。公司股票将于6月1日开市起恢复交易。\n此前，公司因筹划相关事项而申请股票停牌。经过与交易对方的审慎沟通与协商，双方未能就本次交易的关键条款达成一致意见。基于此，为切实维护公司及全体股东利益，经审慎研究，公司决定终止本次控制权变更事项。\n该事项的终止不会对公司正常生产经营产生重大不利影响。公司目前经营状况稳定，各项业务有序开展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0216","301096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639600387","title":"百诚医药最新公告：终止筹划控制权变更事项股票复牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2639600387","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2639600387?lang=zh_cn&edition=full","pubTime":"2026-05-31 15:40","pubTimestamp":1780213206,"startTime":"0","endTime":"0","summary":"百诚医药(301096.SZ)公告称，公司在停牌期间与交易对方就控制权变更事项进行充分探讨，但因涉及事项较多，经慎重考虑，决定终止筹划此次控制权变更。公司股票将于2026年6月1日开市起复牌，终止该事项不会对公司生产经营造成不利影响。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026053100003515.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301096","BK0216"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638902175","title":"百诚医药(301096.SZ)：相关各方正在积极推进公司控制权变更事项 继续停牌","url":"https://stock-news.laohu8.com/highlight/detail?id=2638902175","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2638902175?lang=zh_cn&edition=full","pubTime":"2026-05-26 17:28","pubTimestamp":1779787738,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百诚医药(301096.SZ)发布公告，公司控股股东、实际控制人邵春能先生、楼金芳女士及其一致行动人正在筹划涉及公司控制权变更的重大事项。截止本公告日，相关各方正在积极推进上述事项的工作，公司预计无法在2026年5月27日(星期三)开市起复牌。根据深圳证券交易所的相关规定，经公司向深圳证券交易所申请，公司股票将于2026年5月27日(星期三)开市起继续停牌，预计继续停牌时间不超过3个交易日。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1446032.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0216","301096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638567060","title":"连续两年亏损、长期处于破发状态，百诚医药谋划易主","url":"https://stock-news.laohu8.com/highlight/detail?id=2638567060","media":"蓝鲸财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2638567060?lang=zh_cn&edition=full","pubTime":"2026-05-26 12:08","pubTimestamp":1779768507,"startTime":"0","endTime":"0","summary":"据百诚医药2026年一季报显示，邵春能、楼金芳夫妻二人持股比例分别为18.55%和13.22%，据此合计持股约31.77%。2021年底，百诚医药登陆深交所创业板，不过，公司长期处于破发状态，发行价为79.60元，而停牌前股价为64.60元。对于亏损的原因，百诚医药在2024年年报中解释，报告期内营业收入变动原因主要系公司仿制药业务受集采、 MAH 制度等政策的影响，营业收入下降。今年以来，CRO行业掀起了一轮整合与易主潮。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1779768465065578325","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK0216","301096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1192233326","title":"百诚医药宣布自5月25日起停牌 因控制权或生变","url":"https://stock-news.laohu8.com/highlight/detail?id=1192233326","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1192233326?lang=zh_cn&edition=full","pubTime":"2026-05-24 15:43","pubTimestamp":1779608591,"startTime":"0","endTime":"0","summary":"杭州百诚医药科技股份有限公司发布公告称，公司股票自5月25日开市起停牌，以待潜在控制权变更事项的推进。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["301096","BK0216"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1787300095013,"stockEarnings":[{"period":"1week","weight":0.0312},{"period":"1month","weight":0.2988},{"period":"3month","weight":-0.2121},{"period":"6month","weight":0.0471},{"period":"1year","weight":-0.0986},{"period":"ytd","weight":-0.1092}],"compareEarnings":[{"period":"1week","weight":-0.0059},{"period":"1month","weight":0.0102},{"period":"3month","weight":-0.0509},{"period":"6month","weight":-0.0437},{"period":"1year","weight":0.0365},{"period":"ytd","weight":-0.0164}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"杭州百诚医药科技股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"11216人(较上一季度增加0.95%)","perCapita":"7408股","listingDate":"2021-12-20","address":"浙江省杭州市临平区临平街道绿洲路159号","registeredCapital":"10922万元","survey":" 杭州百诚医药科技股份有限公司的主营业务是为各类制药企业、医药研发投资企业提供医药技术受托研发服务（CRO业务）、研发技术成果转化服务、定制研发生产服务（CDMO）。公司的主要产品是药学研究、临床试验、注册申报、研发技术成果转化、定制研发生产服务（CDMO）、自主创新药物研发、受托创新药物研发。公司先后获得“国家高新技术企业”“省级重点企业研究院”“省级技术中心”等荣誉。","listedPrice":79.6},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百诚医药(301096)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百诚医药(301096)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百诚医药,301096,百诚医药股票,百诚医药股票老虎,百诚医药股票老虎国际,百诚医药行情,百诚医药股票行情,百诚医药股价,百诚医药股市,百诚医药股票价格,百诚医药股票交易,百诚医药股票购买,百诚医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百诚医药(301096)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百诚医药(301096)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}